Cargando…

Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR)

BACKGROUND: The enhanced knowledge of cancer biology has led to considerable advancement in systemic therapy for advanced breast cancer. Recently, studies showed that cyclin-dependent kinase (CDK) 4/6 inhibitor, when added to endocrine therapy, had improved the outcomes of patients with advanced ER-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alomran, Reem, White, Michelle, Bruce, Melissa, Bressel, Mathias, Roache, Susan, Karroum, Lama, Hanna, Gerard G., Siva, Shankar, Goel, Shom, David, Steven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989018/ https://www.ncbi.nlm.nih.gov/pubmed/33757458 http://dx.doi.org/10.1186/s12885-021-08042-w

Ejemplares similares

Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer
por: Weykamp, Fabian, et al.
Publicado: (2020)

Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients
por: König, Laila, et al.
Publicado: (2020)

Effectiveness of Stereotactic Ablative Radiotherapy for Systemic Therapy Respondents with Inoperable Pulmonary Oligometastases and Oligoprogression
por: Ho, Chin-Beng, et al.
Publicado: (2023)

Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancer()
por: Levy, Antonin, et al.
Publicado: (2023)

An analysis of respiratory induced kidney motion on four-dimensional computed tomography and its implications for stereotactic kidney radiotherapy
por: Siva, Shankar, et al.
Publicado: (2013)

Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial
por: David, Steven, et al.
Publicado: (2019)

Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma
por: Schoenhals, Jonathan E., et al.
Publicado: (2021)

Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer
por: Kissel, Manon, et al.
Publicado: (2019)

Outcomes of Stereotactic Body Radiotherapy for Metastatic Colorectal Cancer With Oligometastases, Oligoprogression, or Local Control of Dominant Tumors
por: Ji, Xiaoqin, et al.
Publicado: (2021)

Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study
por: Triggiani, Luca, et al.
Publicado: (2017)

Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer
por: Wang, Zhen, et al.
Publicado: (2021)

Combining Radiotherapy and Immunotherapy in Metastatic Breast Cancer: Current Status and Future Directions
por: David, Steven, et al.
Publicado: (2022)

Comment on ‘Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study’
por: Bravo, Isabel
Publicado: (2018)

Prognostic Factors and Optimal Response Interval for Stereotactic Body Radiotherapy in Patients With Lung Oligometastases or Oligoprogression From Colorectal Cancer
por: Li, Shuai, et al.
Publicado: (2019)

Erratum to combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer
Publicado: (2022)

Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer
por: Lu, Shao-Lun, et al.
Publicado: (2016)

Reply to ‘Comment on ‘Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study’’
por: Triggiani, Luca, et al.
Publicado: (2018)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2023)

Stereotactic body radiation therapy (SBRT) of adrenal gland metastases in oligometastatic and oligoprogressive disease
por: Reshko, Leonid B., et al.
Publicado: (2021)

Role of Consolidative Stereotactic Body Radiation Therapy in Oligoresistant/Oligoprogressive Pulmonary Parenchymal Metastases
por: Berber, Tanju, et al.
Publicado: (2022)

Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review
por: Yaney, Alexander, et al.
Publicado: (2022)

Stereotactic Radiation for Oligometastatic and Oligoprogressive Stage IV Breast Cancer: A Case-based Review
por: Freedman, Gary M., et al.
Publicado: (2023)

SABR in oligometastatic breast cancer: Current status and future directions
por: Stewart, Rachel, et al.
Publicado: (2021)

Stereotactic Body Radiation Therapy to a Splenic Metastasis in Oligoprogressive Non-small Cell Lung Cancer
por: Kim, Daniel W., et al.
Publicado: (2019)

Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma?
por: Rühle, Alexander, et al.
Publicado: (2019)

Safety, Efficacy, and Patterns of Failure After Single-Fraction Stereotactic Body Radiation Therapy (SBRT) for Oligometastases
por: Sogono, Paolo, et al.
Publicado: (2021)

Successful treatment of induced oligometastasis and repeated oligoprogression of advanced lung adenocarcinoma with immunotherapy and radiotherapy
por: Lee, Ho Young, et al.
Publicado: (2022)

Stereotactic body radiation therapy for the treatment of oligoprogression on androgen receptor targeted therapy in castration-resistant prostate cancer
por: Nguyen, Thu-Cuc, et al.
Publicado: (2018)

AB013. Treatment of thymic oligometastastic or oligoprogressive lesions with hypofractionated radiation therapy or stereotactic body radiation therapy
por: Jackson, Christopher B., et al.
Publicado: (2022)

The Effectiveness and Safety of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Oligoprogressive Breast Cancer: A Systematic Review
por: Yan, Bernie, et al.
Publicado: (2023)

A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer
por: Akanda, Zarique Z., et al.
Publicado: (2021)

Stereotactic Body Radiotherapy for Primary Prostate Cancer
por: Kothari, Gargi, et al.
Publicado: (2018)

A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II)
por: Siva, Shankar, et al.
Publicado: (2016)

A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol
por: Pryor, David, et al.
Publicado: (2021)

Stereotactic Body Radiation Therapy (SBRT) for Oligorecurrent/Oligoprogressive Mediastinal and Hilar Lymph Node Metastasis: A Systematic Review
por: Cozzi, Salvatore, et al.
Publicado: (2022)

NeoAdjuvant pembrolizumab and STEreotactic radiotherapy prior to nephrectomy for renal cell carcinoma (NAPSTER): A phase II randomised clinical trial
por: Ali, Muhammad, et al.
Publicado: (2023)

Oligoprogression in Non-Small Cell Lung Cancer
por: Harada, Daijiro, et al.
Publicado: (2021)

Technical know‐how in stereotactic ablative radiotherapy (SABR)
por: Lo, Simon S., et al.
Publicado: (2016)

Stereotactic body radiation therapy for oligoprogression of metastatic disease from gastrointestinal cancers: A novel approach to extend chemotherapy efficacy
por: Wray, Justin, et al.
Publicado: (2017)

Metastasis-Directed Radiotherapy for Oligoprogressive Castration-Resistant Prostate Cancer Recurrence Revealed by Choline PET/CT
por: Kitajima, Kazuhiro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vl6qe5jampuvrc3d0da9lbo9kq